Alveolus Bio

Executive Summary

Alveolus Bio is a Philadelphia-based biotech company founded in 2021, pioneering a microbiome approach to chronic and infectious lung diseases. Its proprietary resMIT platform delivers engineered bacteria directly to the lungs to modulate host-microbe interactions. The lead indication is idiopathic pulmonary fibrosis (IPF), where the therapy targets fibroblast dysfunction, and it is also being developed for neutrophilic inflammation conditions like non-cystic fibrosis bronchiectasis (NCFBE) and COPD. The platform leverages naturally occurring lung microbes to restore homeostasis, offering a novel mechanism distinct from existing anti-fibrotic or anti-inflammatory drugs. As a private company in the approved stage, Alveolus Bio has not disclosed its total funding or valuation but has a focused pipeline and a strong scientific team. The company's approach addresses significant unmet needs in lung diseases with limited treatment options. Key upcoming milestones are expected to include the progression of preclinical studies toward clinical trials, along with potential strategic partnerships to accelerate development. Alveolus Bio's innovative platform and early-stage positioning make it a compelling candidate in the microbiome therapeutics space.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for IPF Program60% success
• Q3 2026Preclinical Data Readout for NCFBE/COPD70% success
• Q3 2026Strategic Partnership or Licensing Deal50% success